Cargando…

Production of Transgenic Calves Expressing an shRNA Targeting Myostatin

Myostatin (MSTN) is a well-known negative regulator of muscle growth. Animals that possess mutations within this gene display an enhanced muscling phenotype, a desirable agricultural trait. Increased neonatal morbidity is common, however, resulting from complications arising from the birth of offspr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tessanne, K, Golding, MC, Long, CR, Peoples, MD, Hannon, G, Westhusin, ME
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Subscription Services, Inc., A Wiley Company 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288734/
https://www.ncbi.nlm.nih.gov/pubmed/22139943
http://dx.doi.org/10.1002/mrd.22007
_version_ 1782224825462292480
author Tessanne, K
Golding, MC
Long, CR
Peoples, MD
Hannon, G
Westhusin, ME
author_facet Tessanne, K
Golding, MC
Long, CR
Peoples, MD
Hannon, G
Westhusin, ME
author_sort Tessanne, K
collection PubMed
description Myostatin (MSTN) is a well-known negative regulator of muscle growth. Animals that possess mutations within this gene display an enhanced muscling phenotype, a desirable agricultural trait. Increased neonatal morbidity is common, however, resulting from complications arising from the birth of offspring with increased fetal muscle mass. The objective of the current research was to generate an attenuated MSTN-null phenotype in a large-animal model using RNA interference to enhance muscle development without the detrimental consequences of an inactivating mutation. To this end, we identified a series of short interfering RNAs that demonstrated effective suppression of MSTN mRNA and protein levels. To produce transgenic offspring capable of stable MSTN suppression in vivo, a recombinant lentiviral vector expressing a short hairpin RNA (shRNA) targeting MSTN for silencing was introduced into bovine fetal fibroblasts. These cells were used as nucleus donors for somatic cell nuclear transfer (SCNT). Twenty blastocysts were transferred into seven recipient cows resulting in five pregnancies. One transgenic calf developed to term, but died following delivery by Caesarean-section. As an alternative strategy, microinjection of recombinant lentiviral particles into the perivitelline space of in vitro-produced bovine zygotes was utilized to produce 40 transgenic blastocysts that were transferred into 14 recipient cows, resulting in 7 pregnancies. Five transgenic calves were produced, of which three expressed the transgene. This is the first report of transgenic livestock produced by direct injection of a recombinant lentivirus, and expressing transgenes encoding shRNAs targeting an endogenous gene (myostatin) for silencing.
format Online
Article
Text
id pubmed-3288734
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Wiley Subscription Services, Inc., A Wiley Company
record_format MEDLINE/PubMed
spelling pubmed-32887342013-02-08 Production of Transgenic Calves Expressing an shRNA Targeting Myostatin Tessanne, K Golding, MC Long, CR Peoples, MD Hannon, G Westhusin, ME Mol Reprod Dev Research Articles Myostatin (MSTN) is a well-known negative regulator of muscle growth. Animals that possess mutations within this gene display an enhanced muscling phenotype, a desirable agricultural trait. Increased neonatal morbidity is common, however, resulting from complications arising from the birth of offspring with increased fetal muscle mass. The objective of the current research was to generate an attenuated MSTN-null phenotype in a large-animal model using RNA interference to enhance muscle development without the detrimental consequences of an inactivating mutation. To this end, we identified a series of short interfering RNAs that demonstrated effective suppression of MSTN mRNA and protein levels. To produce transgenic offspring capable of stable MSTN suppression in vivo, a recombinant lentiviral vector expressing a short hairpin RNA (shRNA) targeting MSTN for silencing was introduced into bovine fetal fibroblasts. These cells were used as nucleus donors for somatic cell nuclear transfer (SCNT). Twenty blastocysts were transferred into seven recipient cows resulting in five pregnancies. One transgenic calf developed to term, but died following delivery by Caesarean-section. As an alternative strategy, microinjection of recombinant lentiviral particles into the perivitelline space of in vitro-produced bovine zygotes was utilized to produce 40 transgenic blastocysts that were transferred into 14 recipient cows, resulting in 7 pregnancies. Five transgenic calves were produced, of which three expressed the transgene. This is the first report of transgenic livestock produced by direct injection of a recombinant lentivirus, and expressing transgenes encoding shRNAs targeting an endogenous gene (myostatin) for silencing. Wiley Subscription Services, Inc., A Wiley Company 2012-03 2011-11-18 /pmc/articles/PMC3288734/ /pubmed/22139943 http://dx.doi.org/10.1002/mrd.22007 Text en Copyright © 2011 Wiley Periodicals, Inc. http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Research Articles
Tessanne, K
Golding, MC
Long, CR
Peoples, MD
Hannon, G
Westhusin, ME
Production of Transgenic Calves Expressing an shRNA Targeting Myostatin
title Production of Transgenic Calves Expressing an shRNA Targeting Myostatin
title_full Production of Transgenic Calves Expressing an shRNA Targeting Myostatin
title_fullStr Production of Transgenic Calves Expressing an shRNA Targeting Myostatin
title_full_unstemmed Production of Transgenic Calves Expressing an shRNA Targeting Myostatin
title_short Production of Transgenic Calves Expressing an shRNA Targeting Myostatin
title_sort production of transgenic calves expressing an shrna targeting myostatin
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288734/
https://www.ncbi.nlm.nih.gov/pubmed/22139943
http://dx.doi.org/10.1002/mrd.22007
work_keys_str_mv AT tessannek productionoftransgeniccalvesexpressinganshrnatargetingmyostatin
AT goldingmc productionoftransgeniccalvesexpressinganshrnatargetingmyostatin
AT longcr productionoftransgeniccalvesexpressinganshrnatargetingmyostatin
AT peoplesmd productionoftransgeniccalvesexpressinganshrnatargetingmyostatin
AT hannong productionoftransgeniccalvesexpressinganshrnatargetingmyostatin
AT westhusinme productionoftransgeniccalvesexpressinganshrnatargetingmyostatin